HIV VACCINE

Multimerized HIV gp120s for Vaccine Development

Brief Description of Technology
An engineered HIV Env glycoprotein that improves antibody-recognition potential for HIV vaccine development.

Technology Overview
Dr. Leo Stamatatos and Dr. Roland Strong have developed a unique and promising approach to developing an effective HIV vaccine by engineering an HIV Env glycoprotein using specific gp120 modifications and multimerization strategies. This multimerized gp120 expands the germline (gl) VRC01-class antibody-recognition potential of the Env, as desired in vaccine development for HIV. HIV-1 broadly neutralizing antibodies (bNAbs) are antibodies capable of neutralizing HIV but efforts to elicit stimulation of such antibodies using recombinant Env (rEnv) have been unsuccessful. One of the reasons for the lack of success is thought to be the inability of the Env proteins used as immunogens to engage B cell receptors (BCRs) that encode the germline of VRC01-class antibodies.

Applications
- Vaccine for HIV

Advantages
- Expands antibody-recognition potential of Env
- Unique and promising approach for HIV vaccine

Market Overview
HIV and AIDS remain a persistent problem for the United States and countries around the world. Worldwide, approximately 37 million people live with HIV. It is estimated that at steady state, routine vaccination demand for vaccines that would prevent infection only is 22-61 million annual doses with a potential market value of $210 million to $2.7 billion, depending on the vaccine product profile.

Investigator Overview
Leo Stamatatos, PhD, Vaccine and Infectious Disease Division
Roland Strong, PhD, Basic Sciences and Vaccine and Infectious Disease Divisions

BUSINESS OPPORTUNITY
Exclusive license
Sponsored research

TECHNOLOGY TYPE
Vaccine development
HIV

STAGE OF DEVELOPMENT
Preclinical in vitro and in vivo
Preparing for phase I clinical trials

PATENT INFORMATION
WO 2016154422

LEARN MORE
Tech ID: 15-016
partnering@fredhutch.org
206-667-4304